CaroElise Ataku: Driven by a Shared Purpose in Producing Personalized Cell Therapies to Fight Cancer

Published on :

Kite specializes in personalized chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain blood cancers and CTSs play a critical role in the process that develops those therapies. Each day, a CTS receives batches of patient cells in their own hands, with each batch representing a new patient. Most of these patients have already exhausted other treatment options. The patient focus and the company’s mission to get these therapies to the people who need them most is the foundation of employees’ day-to-day work.

BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Published on :

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Published on :

Arcellx, a privately held clinical- stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.

A Unique Talent Pool is Propelling Philly to become a Top Biotech Cluster

Published on :

As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.

Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma

Published on :

Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma Cartesian Therapeutics, a biopharmaceutical company that specializes in mRNA-engineered cell therapy, recently announced [….]

Cell and Gene Therapy’s Future a Complex Mix of Promise and Pitfalls

Published on :

At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer

Published on :

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]